A Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC)
Status:
Completed
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
To characterize the safety profile of ARGX-110 administered as mono- or combination therapy
to patients with NPC at various stages of its natural history (adjuvant vs. metastatic).